Royalty Pharma 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	2-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'RPRX	'
Entity Common Stock, Shares Outstanding	'	23,097,412
Entity Registrant Name	'REPROS THERAPEUTICS INC.	'
Entity Central Index Key	'0000897075	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$68,012	$75,807
Prepaid expenses and other current assets	583	189
Total current assets	68,595	75,996
Fixed assets, net	64	75
Other assets, net	3,150	2,906
Total assets	71,809	78,977
Current Liabilities	'	'
Accounts payable	3,362	2,966
Accrued expenses	547	586
Total current liabilities	3,909	3,552
Commitments & Contingencies (note 6)	'	'
Stockholders' Equity	'	'
Undesignated Preferred Stock, $.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common Stock, $.001 par value, 75,000,000 shares authorized, 23,209,762 and 23,125,565 shares issued, respectively; 23,097,412 and 23,013,215 shares outstanding, respectively	23	23
Additional paid-in capital	315,429	314,405
Cost of treasury stock, 112,350 shares	-1,380	-1,380
Deficit accumulated during the development stage	-246,172	-237,623
Total stockholders' equity	67,900	75,425
Total liabilities and stockholders' equity	$71,809	$78,977

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	23,209,762	23,125,565
Common Stock, shares outstanding	23,097,412	23,013,215
Treasury stock, shares	112,350	112,350
Undesignated Preferred Stock [Member]	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, issued	0	0
Preferred Stock, outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		319 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Revenues and other income	'	'	'
Licensing fees	$0	$0	$28,755
Product royalties	0	0	627
Research and development grants	0	0	1,219
Interest income	2	1	16,313
Gain on disposal of fixed assets	0	0	102
Other Income	0	0	1,003
Total revenues and other income	2	1	48,019
Expenses	'	'	'
Research and development	7,325	6,308	225,496
General and administrative	1,226	1,067	58,964
Other Expense	0	0	388
Total expenses	8,551	7,375	284,848
Loss from continuing operations	-8,549	-7,374	-236,829
Loss from discontinued operations	0	0	-1,828
Gain on disposal of discontinued operation	0	0	939
Net loss before cumulative effect of change in accounting principle	-8,549	-7,374	-237,718
Cumulative effect of change in accounting principle	0	0	-8,454
Net loss	($8,549)	($7,374)	($246,172)
Basic and diluted loss per share	($0.37)	($0.41)	'
Shares used in loss per share calculation:	'	'	'
Basic	23,033	18,182	'
Diluted	23,033	18,182	'

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Deficit Accumulated During the Development Stage
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$23,034	$17	$234,299	($1,380)	($209,902)
Beginning Balance (in shares) at Dec. 31, 2012	'	17,272,505	'	112,350	'
Stock based option compensation	629	0	629	0	0
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants	0	1	-1	0	0
Issuance of 871,634 shares of common stock for the cashless exercise of 872,133 Series A Warrants (in shares)	'	871,634	'	0	'
Issuance of 612,197 shares of common stock for the cashless exercise of 713,741 Series B Warrants	0	1	-1	0	0
Issuance of 612,197 shares of common stock for the cashless exercise of 713,741 Series B Warrants (in shares)	'	612,197	'	0	'
Net loss	-7,374	0	0	0	-7,374
Ending Balance at Mar. 31, 2013	16,289	19	234,926	-1,380	-217,276
Ending Balance (in shares) at Mar. 31, 2013	'	18,756,336	'	112,350	'
Beginning Balance at Dec. 31, 2013	75,425	23	314,405	-1,380	-237,623
Beginning Balance (in shares) at Dec. 31, 2013	'	23,125,565	'	112,350	'
Stock based option compensation	920	0	920	0	0
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share)	104	0	104	0	0
Exercise of stock options to purchase common stock stock for cash ($1.56 to $9.60 per share) (in shares)	'	15,000	'	0	'
Issuance of 69,197 shares of common stock for the cashless exercise of 91,664 stock options	'	69,197	'	0	'
Net loss	-8,549	0	0	0	-8,549
Ending Balance at Mar. 31, 2014	$67,900	$23	$315,429	($1,380)	($246,172)
Ending Balance (in shares) at Mar. 31, 2014	'	23,209,762	'	112,350	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Issuance of shares of common stock for the cashless exercise of Series A Warrants stock options	872,133	'
Issuance of shares of common stock for the cashless exercise of Series B Warrants stock options	'	713,741
Issuance of shares of common stock for the cashless exercise of stock options	91,664	'
Maximum [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	9.6	'
Minimum [Member]	'	'
Exercise of stock option to purchase common stock for cash, share price	1.56	'

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		319 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash Flows from Operating Activities	'	'	'
Net loss	($8,549)	($7,374)	($246,172)
Gain on disposal of discontinued operations	0	0	-939
Gain on disposal of fixed assets	0	0	-102
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Noncash financing costs	0	0	316
Noncash inventory impairment	0	0	4,417
Noncash patent impairment	0	0	2,614
Noncash other income	'	'	-709
Noncash decrease in accounts payable	0	0	-1,308
Depreciation and amortization	58	53	4,616
Noncash stock-based compensation	920	629	16,396
Common stock issued for agreement not to compete	0	0	200
Series B Preferred Stock issued for consulting services	0	0	18
Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994):	'	'	'
Increase in receivables	0	0	-199
Increase in inventory	0	0	-4,447
(Increase) decrease in prepaid expenses and other current assets	-393	51	-280
Increase (decrease) in accounts payable and accrued expenses	350	-121	11,611
Net cash used in operating activities	-7,614	-6,762	-213,968
Cash Flows from Investing Activities	'	'	'
Change in trading marketable securities	0	0	-191
Capital expenditures	0	-45	-2,486
Purchase of other assets	-285	-255	-6,667
Proceeds from sale of fixed assets	0	0	225
Cash acquired in purchase of FTI	0	0	3
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period	0	0	138
Proceeds from sale of the assets of FTI	0	0	2,250
Increase in net assets held for disposal	0	0	-213
Net cash used in investing activities	-285	-300	-6,941
Cash Flows from Financing Activities	'	'	'
Proceeds from issuance of common stock and warrants, net of offering costs	0	0	284,195
Exercise of stock options & warrants	104	0	1,091
Proceeds from a shareholder transaction	0	0	327
Proceeds from issuance of preferred stock	0	0	23,688
Purchase of treasury stock	0	0	-21,487
Proceeds from issuance of notes payable	0	0	2,839
Principal payments on notes payable	0	0	-1,732
Net cash provided by financing activities	104	0	288,921
Net increase (decrease) in cash and cash equivalents	-7,795	-7,062	68,012
Cash and cash equivalents at beginning of period	75,807	24,212	0
Cash and cash equivalents at end of period	$68,012	$17,150	$68,012

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Proceeds from sale of subsidiary, operating losses during 1990 phase-out period	$12,345

Organization_Operations_and_Li

Organization, Operations and Liquidity	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Operations and Liquidity	'
	NOTE 1 — Organization, Operations and Liquidity
	Repros Therapeutics Inc. (the “Company,” “RPRX,” “Repros,” or “we,” “us” or “our”) was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
	Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. We are developing Androxal® for men of reproductive age with low testosterone levels. Androxal® treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. We have completed two pivotal Phase 3 efficacy studies and we are currently conducting two Phase 3 studies, ZA-304 and ZA-305, against approved testosterone replacement products.
	Proellex®, our product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. We completed a dose escalating study to demonstrate both safety and efficacy signals in low oral doses of Proellex® and we are conducting a Phase 2 study in the treatment of endometriosis. Additionally, the Food and Drug Administration has accepted an Investigational New Drug Application for vaginally delivered Proellex®. As a result, we completed a Phase 1/2 vaginal administration study for uterine fibroids.
	Our product development pipeline, with dates as expected as of the date of this report, is summarized in the table below:
	Product Candidate (Indication)	Status	Next Expected Milestone(s)
	Androxal®
	Secondary Hypogonadism	Phase 3	Complete DEXA study (Q4 2014)
			Complete ZA-304 and ZA-305 studies (Q4 2014)
	Proellex®
	Uterine Fibroids	Phase 2	Initiate a Phase 2B study (vaginal delivery) (2014)
			Submit Phase 2 study protocol to FDA (oral delivery) (2014)
	Endometriosis	Phase 2	Fully enroll Phase 2 study (oral delivery) (2014)
	As of March 31, 2014, we had accumulated losses of $246.2 million, approximately $68.0 million in cash and cash equivalents, and accounts payable and accrued expenses of approximately $3.9 million, in the aggregate. We anticipate that our current liquidity will be sufficient to continue the development of our product candidates through the New Drug Application filing of both products. We continue to explore potential corporate partnering opportunities for assistance in the clinical development funding and commercialization of our products, as appropriate; however, there can be no assurance that an acceptable corporate partnering opportunity will be successfully completed or that our current liquidity will be sufficient to fund all of our product development needs.

Patents_and_Patent_Application

Patents and Patent Applications	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Patents and Patent Applications	'
	NOTE 2 — Patents and Patent Applications
	As of March 31, 2014, the Company had approximately $3,150,000 in capitalized patent and patent application costs reflected on its balance sheet. Of this amount, $1,844,000 relates to Androxal® and $1,306,000 relates Proellex®.
	Should the Company not continue development of either drug candidate or should the Company not continue as a going concern, the remaining capitalized patent costs may not be recoverable, which would result in charges to operating results in future periods.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	NOTE 3 — Accrued Expenses
	Accrued expenses consist of the following (in thousands):
		March 31, 2014		December 31, 2013
	Research and development costs	$	234	$	89
	Patent costs		224		188
	Personnel related costs		42		196
	Other		47		113
	Total	$	547	$	586

Loss_Per_Share

Loss Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Loss Per Share	'
	NOTE 4 — Loss Per Share
	Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed using the average share price for the period and applying the treasury stock method to potentially dilutive outstanding options. In all applicable periods, all potential common stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share.
	The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2014 and 2013 (in thousands, except per share amounts):
		Three Months Ended March 31,
		2014		2013
	Net loss	$	-8,549	$	-7,374
	Average common shares outstanding		23,033		18,182
	Basic and diluted loss per share	$	-0.37	$	-0.41
	Potential common stock of 4,086,885 and 3,968,500 common shares underlying stock options and warrants for the periods ended March 31, 2014 and 2013, respectively, were excluded from the above calculation of diluted loss per share because they were anti-dilutive. Other potential common stock at March 31, 2014 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 809,805 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering. Other potential common stock at March 31, 2013 includes Series A Warrants to purchase 877,137 shares of our common stock at an exercise price of $0.01 and Series B Warrants to purchase 855,680 shares of our common stock at an exercise price of $2.49 issued in our February 8, 2011 public offering.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 5 — Stock-Based Compensation
	During the three month period ended March 31, 2014, the Compensation Committee of the Company’s Board of Directors approved grants of options to purchase 273,000 shares of our common stock to employees under the 2011 Equity Incentive Plan. All of these options vest over a three year period. Additionally, during the three month period ended March 31, 2014, 111,244 options either expired or were forfeited.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 6 — Commitments and Contingencies
	Therapeutic uses of our Androxal® product candidate are covered in the United States by nine issued U.S. patents and five pending patent applications. Foreign coverage of therapeutic uses of our Androxal® product candidate includes 66 issued foreign patents and 65 foreign pending patent applications. The issued patents and pending applications relate to methods for treating certain conditions including the treatment of testosterone deficiency in men, the treatment of diabetes mellitus Type 2, the treatment of metabolic syndrome and conditions associated therewith, and the treatment of infertility in hypogonadal men. Androxal® (the trans-isomer of clomiphene) is purified from clomiphene citrate. A third party individual holds two issued patents related to the use of anti-estrogen such as clomiphene citrate and others for use in the treatment of disorders related to androgen deficiency. We requested re-examination of one of these patents by the U.S. Patent and Trademark Office (“PTO”) based on prior art. The patent holder amended the claims in the re-examination proceedings, which led the PTO to determine that the amended claims were patentable in view of those publications under consideration and a re-examination certificate was issued. We subsequently filed a second request for re-examination by the PTO in light of a number of additional publications. The request was granted and all of the claims were finally rejected by the PTO in the re-examination. The patent holder appealed the rejections to the PTO Board of Patent Appeals and Interferences (the “PTO Board”) which ultimately reversed the rejections of several dependent claims in view of those publications under consideration. The patent holder filed a Notice of Appeal to the Federal Circuit on September 28, 2010 contesting the rejections maintained by the PTO Board. A decision was rendered by the Court of Appeals for the Federal Circuit on December 12, 2011, affirming the rejection of the appealed claims. The PTO issued an Ex Parte Reexamination Certificate on April 29, 2013, canceling the rejected claims and confirming the patentability of the remaining claims. Nevertheless, we believe that our development of Androxal® does not infringe any of the remaining claims and that all of the remaining claims are invalid on various grounds including additional prior art publications. We also believe that the second of these two patents is invalid in view of published prior art not considered by the PTO. If necessary, we intend to vigorously defend any and all claims that may be brought by the holder of such patents in a court of competent jurisdiction in order to develop Androxal® further. Adverse determinations in litigation proceedings could require us to seek licenses which may not be available on commercially reasonable terms, or at all, or subject us to significant liabilities, in which case we may not be able to successfully commercialize or out-license Androxal® until such patents expire or are otherwise no longer in force.
	On July 19, 2013, we received a letter from Dr. Harry Fisch threatening to file a lawsuit against us and two of our executive officers (Joseph S. Podolski, President and Chief Executive Officer and Ron Wiehle, Executive Vice President), seeking addition of Dr. Harry Fisch as an inventor on three of our patents, U.S. Patent Nos. 7,173,064, 7,737,185 and 7,759,360, covering therapeutic uses of Androxal®. We believe that these allegations are without merit and on August 2, 2013, we commenced a lawsuit against Dr. Fisch in the U.S. District Court for the Southern District of Texas seeking a declaratory judgment that he should not be added as an inventor to any of these patents. On October 2, 2013, Dr. Fisch filed his answer and counterclaims to our complaint. Dr. Fisch asserted counterclaims seeking correction of inventorship of the three patents at issue to name Dr. Fisch as a co-inventor of the applications leading these patents. Dr. Fisch subsequently stipulated that he does not claim to be a co-inventor of U.S. Patent No. 7,173,064. Dr. Fisch also seeks reasonable attorney’s fees. Due to the preliminary status of the lawsuit and uncertainties related to litigation, we are unable to evaluate the likelihood of either a favorable or unfavorable outcome.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following (in thousands):
		March 31, 2014		December 31, 2013
	Research and development costs	$	234	$	89
	Patent costs		224		188
	Personnel related costs		42		196
	Other		47		113
	Total	$	547	$	586

Loss_Per_Share_Tables

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Calculation of Loss Per Share	'
	The following table presents information necessary to calculate loss per share for the three month periods ended March 31, 2014 and 2013 (in thousands, except per share amounts):
		Three Months Ended March 31,
		2014		2013
	Net loss	$	-8,549	$	-7,374
	Average common shares outstanding		23,033		18,182
	Basic and diluted loss per share	$	-0.37	$	-0.41

Organization_Operations_and_Li1

Organization, Operations and Liquidity (Product Development Pipeline) (Details)	3 Months Ended
	Mar. 31, 2014
Androxal [Member] | Secondary Hypogonadism [Member]	'
Product Information [Line Items]	'
Status	'Phase 3
Next Expected Milestone(s)	'Complete DEXA study (Q4 2014) Complete ZA-304 and ZA-305 studies (Q4 2014)
Proellex [Member] | Uterine Fibroids 1 [Member]	'
Product Information [Line Items]	'
Status	'Phase 2
Next Expected Milestone(s)	'Initiate a Phase 2B study (vaginal delivery) (2014) Submit Phase 2 study protocol to FDA (oral delivery) (2014)
Proellex [Member] | Endometriosis [Member]	'
Product Information [Line Items]	'
Status	'Phase 2
Next Expected Milestone(s)	'Fully enroll Phase 2 study (oral delivery) (2014)

Organization_Operations_and_Li2

Organization, Operations and Liquidity (Additional Information) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Aug. 19, 1987
Product Information [Line Items]	'	'	'	'	'
Deficit accumulated during the development stage	($246,172,000)	($237,623,000)	'	'	'
Cash and cash equivalents	68,012,000	75,807,000	17,150,000	24,212,000	0
Accounts payable and accrued expenses	$3,900,000	'	'	'	'

Patents_and_Patent_Application1

Patents and Patent Applications (Additional Information) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	$3,150,000	$2,906,000
Androxal [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	1,844,000	'
Proellex [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Capitalized patent and patent application costs	$1,306,000	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Accrued Liabilities [Line Items]	'	'
Research and development costs	$234	$89
Patent costs	224	188
Personnel related costs	42	196
Other	47	113
Total	$547	$586

Loss_Per_Share_Calculation_of_

Loss Per Share (Calculation of Loss Per Share) (Details) (USD $)	3 Months Ended		319 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Net loss	($8,549)	($7,374)	($246,172)
Average common shares outstanding	23,033	18,182	'
Basic and diluted loss per share	($0.37)	($0.41)	'

Loss_Per_Share_Additional_Info

Loss Per Share (Additional Information) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	4,086,885	3,968,500
Series A Warrants [Member]	'	'
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	877,137	877,137
Warrants, exercise price per share	0.01	0.01
Series B Warrants [Member]	'	'
Earnings Per Share Disclosure [Line Items]	'	'
Anti-dilutive shares of common stock excluded from computation of earning per share	809,805	855,680
Warrants, exercise price per share	2.49	2.49

StockBased_Compensation_Additi

Stock-Based Compensation (Additional Information) (Details) (2011 Equity Incentive Plan Member)	3 Months Ended
	Mar. 31, 2014
2011 Equity Incentive Plan Member	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	273,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	111,244

Commitments_and_Contingencies_

Commitments and Contingencies (Additional Information) (Details)	Mar. 31, 2014
Domestic [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	9
Number of pending patent applications	5
Foreign [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	66
Number of pending patent applications	65
Third Party [Member]	'
Commitments and Contingencies [Line Items]	'
Number of patents	2